JTJunichiro Tezuka

Junichiro Tezuka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Junichiro Tezuka has a total of 208 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current practices of topical and systemic novel molecular-targeted therapies for pediatric atopic dermatitis in Japan: A nationwide survey of physicians providing pediatric allergy care

    by Kiwako Yamamoto-Hanada, Masaki Futamura, Yukiko Hiraguchi, Satoshi Horino, Takanori Imai, Toshiko Itazawa, Asuka Kawaguchi, Teruaki Matsui, Manabu Miyamoto, Mizuho Nagao, et al.

    Background: The availability of new topical molecular-targeted therapies, biologics, and oral Janus kinase (JAK) inhibitors has expanded treatment options for pediatric atopic dermatitis (AD). However, real-world prescribing patterns, rationale for use, and challenges in clinical decision-making remain unclear. This study aimed to characterize contemporary management practices and identify barriers to optimal therapy among physicians providing pediatric allergy care in Japan. Methods: We conducted a nationwide, cross-sectional, anonymous online survey of members of the Japanese Society of Pediatric Allergy and Immunology from July 2025 to August 2025. The questionnaire, developed by AD specialists, captured physician characteristics, treatment strategies, utilization of topical and systemic agents, adverse events, and perceived difficulties in clinical practice. Descriptive statistics were used to summarize responses. Results: A total of 488 physicians participated. Most were experienced pediatric specialists who reported high adherence to AD guidelines and frequent use of proactive therapy. Difamilast and delgocitinib were widely used among topical nonsteroidal agents. Biologics had been prescribed by 65.6% of respondents and oral JAK inhibitors by 36.1%, although substantial caution was observed. Safety was the primary factor guiding selection between biologics and JAK inhibitors. Many physicians reported difficulty determining appropriate discontinuation timing for systemic therapies. Conclusions: Japanese pediatric allergy physicians actively employ novel topical and systemic therapies but face persistent uncertainty regarding long-term management and treatment discontinuation. Strengthening standardized topical care, clarifying exit strategies for systemic therapy, and enhancing long-term safety data are essential to optimize pediatric AD management.

  • Open Access

    Consensus definition of clinical remission in asthma for the Japanese asthma prevention and management guidelines (JGL 2024): A modified delphi survey and comprehensive review

    by Hiroyuki Nagase, Norihiro Harada, Junichiro Tezuka, Masaki Futamura, Mizuho Nagao, Takumi Takizawa, Shigemi Yoshihara, Makoto Nagata, Akio Niimi, Masao Yamaguchi


  • Open Access

    Surveys on the prevalence of pediatric asthma in Japan: A comparison between the 1982, 1992, 2002, 2012, and 2022 surveys conducted in the same region using the same methodology (WJSAAC PhaseⅠ∼Ⅴ)

    by Sankei Nishima, Junichiro Tezuka, Hiroshi Odajima, Satoshi Honjo, Kunitaka Ota, Yuji Gohda, Kazuyoshi Koga, Keijiro Tsuda, Yoshiaki Kanaya, Shuich Yamamoto, et al.


  • Open Access

    Suppressed pediatric asthma hospitalizations during the COVID‐19 pandemic in Japan, from a national survey

    by Seigo Korematsu, Takao Fujisawa, Naruo Saito, Junichiro Tezuka, Katsushi Miura, Ichiro Kobayashi, Ippei Miyata, Yujiro Kosugi, Yuji Gohda, Yumi Koike, et al.

    Background: Acute asthma exacerbation in children is often caused by respiratory infections. In this study, a coordinated national surveillance system for acute asthma hospitalizations and causative respiratory infections was established. We herein report recent trends in pediatric acute asthma hospitalizations since the COVID‐19 pandemic in Japan.Methods: Thirty‐three sentinel hospitals in Japan registered all of their hospitalized pediatric asthma patients and their causal pathogens. The changes in acute asthma hospitalization in children before and after the onset of the COVID‐19 pandemic and whether or not COVID‐19 caused acute asthma exacerbation were investigated.Results: From fiscal years 2010–2019, the median number of acute asthma hospitalizations per year was 3524 (2462–4570), but in fiscal years 2020, 2021, and 2022, the numbers were 820, 1,001, and 1,026, respectively (the fiscal year in Japan is April to March). This decrease was observed in all age groups with the exception of the 3‐ to 6‐year group. SARS‐CoV‐2 was evaluated in 2094 patients from fiscal years 2020–2022, but the first positive case was not detected until February 2022. Since then, only 36 of them have been identified with SARS‐CoV‐2, none of which required mechanical ventilation. Influenza, RS virus, and human metapneumovirus infections also decreased in FY 2020. In contrast, 24% of patients had not been receiving long‐term control medications before admission despite the severity of bronchial asthma.Conclusion: SARS‐CoV‐2 was hardly detected in children with acute asthma hospitalization during the COVID‐19 pandemic. This result indicated that SARS‐CoV‐2 did not induce acute asthma exacerbation in children. Rather, infection control measures implemented against the pandemic may have consequently reduced other respiratory virus infections and thus acute asthma hospitalizations during this period. However, the fact that many hospitalized patients have not been receiving appropriate long‐term control medications is a major problem that should be addressed.


  • Patients with polyethylene glycol allergy can experience immediate-type hypersensitivity reactions after exposure to analog substances

    by Yosuke Yoshimoto, Junichiro Tezuka

    Polyethylene glycol (PEG) allergy has been recently observed after COVID-19 mRNA vaccination. We present a case of a patient with a history of two hospitalisations for unexplained recurrence of immediate-type hypersensitivity reactions and anaphylaxis who was diagnosed with PEG allergy in early childhood. Subsequently, he was instructed to avoid using PEG-containing daily necessities and drugs. However, in middle childhood, he presented with immediate-type hypersensitivity reactions after taking PEG-free antibiotics. The prick test was positive for the whole drug but negative for its active ingredient. PEG can cross-react with compounds with a C–C–O skeleton as analogue substances; accordingly, the presence of a substance with a similar skeleton in the additive may have been the causative factor. Our findings indicate that patients with PEG allergy may experience immediate-type hypersensitivity reactions to analogue substances.


  • Open Access

    Prevalence of Allergic Diseases across All Ages in Japan: A Nationwide Cross-Sectional Study Employing Designated Allergic Disease Medical Hospital Network

    by Yasunori Ito, Taisuke Kato, Koichi Yoshida, Kyohei Takahashi, Yuma Fukutomi, Mizuho Nagao, Tatsuki Fukuie, Hiroshi Matsuzaki, Minoru Gotoh, Akio Tanaka, et al.

    Allergic diseases affect both children and adults, but generation-specific prevalence rates are unclear. An online questionnaire was used from December 2021 to January 2022 to survey the prevalence of allergic diseases among staff and their families of designated allergic disease medical hospitals in Japan. In this study, bronchial asthma (BA), atopic dermatitis (AD), food allergies (FAs), allergic rhinitis (AR), allergic conjunctivitis (AC), metal allergies (MAs), and drug allergies (DAs) were the allergic diseases surveyed. In total, 18,706 individuals were surveyed (median age, 36 years; quartile range, 18-50). Allergic disease was reported in 62.2% of respondents. Across all ages, prevalence rates were as follows: BA (14.7%), AD (15.6%), FAs (15.2%), AR (47.4%), AC (19.5%), MAs (1.9%), and DAs (4.6%). The prevalence of BA and AR was higher in male children, whereas that of FAs and AC was higher in adult females. The prevalence of MAs and DAs peaked during adulthood and predominated among females. Our results suggest that approximately two-thirds of the Japanese population may have an allergic disease, with AR being the most prevalent.


  • Simultaneous oral mite anaphylaxis in siblings, identified by the saturated saline flotation method

    by Yosuke Yoshimoto, Takuya Oda, Masaru Kawamura, Kota Ikari, Junichiro Tezuka

  • Plastic bronchitis in a child with nephrotic syndrome

    by Kenji Maehara, Mari Kurokawa, Junichiro Tezuka, Sooyoung Lee, Yoshitsugu Kaku


  • Charcot–Leyden Crystals in Rapidly Progressing Plastic Bronchitis

    by Kota Ikari, Junichiro Tezuka, Tsubasa Matsumoto, Moeri Tsuji, Masaru Kawamura, Takuya Oda, Shigeharu Ueki


  • Open Access

    Enhanced airway hyperresponsiveness in asthmatic children and mice with A(H1N1)pdm09 infection

    by Taira Ariyoshi, Junichiro Tezuka, Hiroki Yasudo, Yasufumi Sakata, Tamaki Nakamura, Takeshi Matsushige, Hideki Hasegawa, Noriko Nakajima, Akira Ainai, Atsunori Oga, et al.

    Background: Severe asthma exacerbation is an important comorbidity of the 2009 HIN1 pandemic (A(H1N1)pdm09) in asthmatic patients. However, the mechanisms underlying severe asthma exacerbation remain unknown. In this study, airway hyperresponsiveness (AHR) was measured in pediatric asthma patients infected with A(H1N1)pdm09. We also evaluated AHR in asthmatic mice with A(H1N1)pdm09 infection and those with seasonal influenza for comparison.Methods: AHRs in asthmatic children were defined as the provocative acetylcholine concentration causing a 20% reduction in forced expiratory volume in 1 s (PC20). To investigate the pathophysiology using animal models, BALB/c mice aged 6‐8 weeks were sensitized and challenged with ovalbumin. Either mouse‐adapted A(H1N1)pdm09, seasonal H1N1 virus (1 × 105 pfu/20 μl), or mock treatment as a control was administered intranasally. At 3, 7, and 10 days after infection, each group of mice was evaluated for AHR by methacholine challenge using an animal ventilator, flexiVent. Lung samples were resected and observed using light microscopy to assess the degree of airway inflammation.Results: AHRs in the children with bronchial asthma were temporarily increased, and alleviated by 3 months after discharge. AHR was significantly enhanced in A(H1N1)pdm09‐infected asthmatic mice compared to that in seasonal H1N1‐infected mice (p < .001), peaking at 7 days postinfection and then becoming similar to control levels by 10 days postinfection. Histopathological examination of lung tissues showed more intense infiltration of inflammatory cells and severe tissue destruction in A(H1N1)pdm09‐infected mice at 7 days postinfection than at 10 days postinfection.Conclusion: Our results suggest that enhanced AHR could contribute to severe exacerbation in human asthmatic patients with A(H1N1)pdm09 infection.